Table 1.
Description of Prognostic Studies: 6 Publications and 16 Assessments
| Reference | Disease | Biomarker assessed with area under the ROC curve |
|---|---|---|
| Ngo Y, Munteanu M, Messous D, et al14 | HCV | FibroTest, APRI, biopsy |
| Ngo Y, Benhamou Y, Thibault V, et al15 | HBV | FibroTest, APRI, biopsy |
| Naveau S, Gaude G, Asnacios A, et al7 | ALD | FibroTest, APRI, FIB-4, HepaScore, FibroMeter, biopsy |
| Nunes D, Fleming C, Offner G, et al17 | HCV | APRI, FIB-4 |
| Parkes J, Roderick P, Harris S, et al18 | Mixed liver disease | ELF, biopsy |
| Vergniol J, Foucher J, Terrebonne E, et al16 | HCV | FibroTest, APRI, FibroScan, FIB-4, biopsy |
- ALD
alcoholic liver disease
- APRI
aspartate transaminase-platelet ratio index
- HBV
hepatitis B virus
- HCV
hepatitis C virus
- ROC
receiver operating characteristic